Provider Name:
Jeffrey W. Taub, M.D.
Academic Appointment: Professor of Pediatrics
Provider Specialty:
Hematology/Oncology
Areas of Clinical Focus:
Leukemia/Lymphoma/Children with Down syndrome and leukemia/Retinoblastoma/General oncology/Cancer survivorship
Areas of Research/Scholarship Focus:
Childhood leukemia/Leukemia epidemiology
Board Certification(s):
Pediatric Hematology/Oncology/Pediatrics
Primary Practice Name:
Children's Hospital of MI
Primary Practice Address:
3901 Beaubien - 2nd Floor - Carl's Bldg
City:
Detroit
State:
MI
ZIP Code:
48267
Practice Phone Number:
(313)745-5515
Practice Fax:
(313)745-5237
Other Practicing Locations:
Accepted Insurance:
We accept most types on insurance. Please call to confirm that your carrier is on our list.
Languages Spoken: English
Medical School:
University of Western Ontario
Internship:
Victoria Hospital/University of Western Ontario
Residency:
Children's Hospital of Michigan
Fellowship:
Children's Hospital of Michigan
Selected Publications:
1. Taub JW, Matherly LH, Stout M, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down Syndrome cells: a contributing factor to the superior event-free survival of Down Syndrome children with acute myeloid leukemia. Blood 87:3395-3403, 1996.
2. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y. Myeloblasts from Down Syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 11:1594-1595,1997.
3. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down Syndrome and non-Down Syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94:1393-1400, 1999.
4. Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohamad RM, Ravindranath Y, Matherly LH. Cystathionine-β-synthase cDNA transfection alters the sensitivity and metabolism of cytosine arabinoside in CCRF-CEM leukemia cells in vitro and in vivo: a model of Down Syndrome in leukemia. Cancer Research 60:6421-6426, 2000.
5. Taub JW, Konrad MA, Ge Y, Naber JM, Scott JS, Matherly LH, Ravindranath Y. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99:2992-2996, 2002.
6. Ge Y, Jensen TL, Matherly LH, Taub JW. Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood 101: 1551-1557, 2003.
7. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Research 64: 728-735, 2004.
8. Taub JW, Mundschau G, Ge Y, Poulik J, Qureshi F, Jensen TL, Matherly LH, James J, Weschler J, Crispino JD. Prenatal origin of GATA1 mutations may be an initiating step in the development of leukemia in Down syndrome. Blood 104:1588-1589, 2004.
9. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW. Gata1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute 97:226-231, 2005.
10. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G., Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107: 1570-1581, 2006.
11. LaFiura KM, Bielawski DM, Posecion NC, Ostrea EM, Matherly LH, Taub JW, Ge Y. Association between prenatal pesticide exposures and the generation of leukemia-associated t(8;21). Pediatric, Blood and Cancer 49:624-628, 2007.
12. Sharathkumar A, Deborah DeCamillo D, Bhambhani K, Cushing B, Thomas R, Mohamed AN, Ravindranath Y, Taub JW. Children with Hyperdiploid but not Triple Trisomy (+4,+10,+17) Acute Lymphoblastic Leukemia have an Increased Incidence of Extramedullary Relapse on Current Therapies: A Single Institution Experience. American Journal of Hematology 83: 34-40. 2008.
13. Gruhn B, Taub JW, Ge Y, Beck JF, Zell R, Häfer R, Hermann FH, Debatin K-M, Steinbach D. Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia 22: 1692-1697, 2008.
14. Cabelof DC, Patel HV, Chen Q, van Remmen H, Matherly LH, Ge Y, Taub JW. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down Syndrome. Blood 114:2753-2763, 2009.
15. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M,Coustan-Smith E, Leung W, Pui CH, Campana D. Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. Lancet Oncology 11: 543-552, 2010.
16. Xavier AC, Edwards H, Dombkowski AA, Balci TB, Berman JN, Dellaire G, Xie C, Buck SA, Matherly LH, Ge Y, Taub JW. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. PLoSOne 6:e27486, 2011.
17. Caldwell JT, Pitman H, Buck SA, Ge Y, Taub JW. Targeting the wee1 Kinase for Treatment of Pediatric Down Syndrome Acute Myeloid Leukemia. Pediatric Blood and Cancer 61: 1767-1773, 2014.
18. Shaham L, Vendrarmini E, Ge Y, Pitman H, Goren Y, Tijssen M, Birger Y, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Weiss MJ, Israel LL, Lellouche E, Michaeli S, Lellouche JP, Sredni B, Göttgens B, Crispino J, Taub JW*, Izraeli S*. MicroRNA-486-5p in the myeloid leukemias of Down Syndrome. Blood 125: 1292-1301, 2015. [*Co-corresponding authors]
19. Edwards H, Rubenstein M, Dombkowski AA, Caldwell JT, Chu R, Xavier AC, Thummel R, Neely M, Matherly LH, Ge, Y Taub JW. Gene Signature of High White Blood Cell Count in B-precursor Acute Lymphoblastic Leukemia. PlosOne 11(8):e0161539, 2016.
20. Taub JW, Berman JN, Hitzler JH, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Myeloid Leukemia of Down Syndrome (ML-DS): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial. Blood 129: 3304-3313, 2017.
21. Hutchins KK, Savasan S, Thomas RL, Strathdee LA, Wang ZJ, Taub JW. Clinical trial enrollment is associated with improved follow-up rates among survivors of childhood cancer. Journal of Pediatric Hematology Oncology 41:e18-e23, 2019.
22. Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Hitzler JK, Head DR. Pathologic Features of Down Syndrome MDS and AML: A Report From the Children’s Oncology Group Protocol AAML0431. Archives of Pathology & Laboratory Medicine (in press 2019).
23. Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Eng-Juh Yeoh A, Campana D, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 multicenter, randomized phase III trial. Journal of Clinical Oncology 37:2072-2081, 2019.
24. Marusak HA, Harper FW, Taub JW, Rabinak CA. Pediatric cancer, posttraumatic stress and fear-related neural circuitry. International Journal of Hematologic Oncology 8(2):IJH17, 2019
25. Shatara M, Xavier AC, Dombkowski A, Cukovic D, Poulik JM, Altinok D, Ge Y, Taub JW. Monozygotic twins with neuroblastoma IVS and similar molecular profile: a case of likelihood twin-to-twin metastasis. British Journal of Cancer 121:890-893, 2019.
26. Shields JN, Hales EC, Ranspach LE, Luo X, Orr S, Runft D, Dombkowski A, Neely M, Matherly LH, Taub JW, Baker TR, Thummel R. Exposure of larval zebrafish to the insecticide Propoxur induced developmental delays that correlate with behavioral abnormalities and altered expression of hspb9 and hspb11. Toxics 7(4). pii: E50. doi: 10.3390/toxics7040050, 2019.
27. Yankelevich M, Hoogstra D, Abrams J, Chu R, Bhambhami K, Taub, JW. Delayed granulocyte colony-stimulating factor (G-CSF) administration after chemotherapy reduces total G-CSF doses without affecting neutrophil recovery in a randomized clinical study in children with solid tumors. Pediatric Hematology-Oncology 9:1-11, 2020.
Case Reports
1. Persaud Y, Al-Antry E, Shamoun M, Chitlur M, Taub JW. Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis. Journal of Pediatric Hematology Oncology 2020 in press
2. Persaud Y, Seddiq M, Wu YM, Robinson DR, Poulik J, Altinok D, Roarty JD, Mody R, Taub JW. Unusual Clinical Behavior of a Very Late Retinoblastoma Relapse in a Patient with a Germline RB Mutation. Pediatric Blood and Cancer 2021 Aug;68(8):e29064.
Letters to the Editor
1. Taub JW. Here’s how MAD has influenced me over the past 47 years. MAD Magazine December 2018.
2. Taub, Ge Y, Xavier AC. COVID-19 and Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer May 13:e28400, 2020.
Awards/Honors:
[1]Ring Screw Textron in Pediatric Cancer Research
[2]Crain's Detroit Business Newspaper Health Care Hero
[3]Physician Difference Maker Award
